Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
CANTON, Mass., April 20, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 9, 2018 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.
Conference Call Information:
To access the conference call, please dial (888) 698-6931 (U.S.) or (805) 905-2993 (International) and refer to Conference ID: 799-9797. An audio webcast will be accessible from the Investor Relations section of the Company’s website: http://www.collegiumpharma.com/. An archived webcast will be available on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
